Overview
GPCRs are the most commercially important receptor family and among the least forgiving to express. Expression level changes apparent pharmacology, the chosen readout determines which pathway you see, and the host cell background contributes signalling components you may not have accounted for. We design the construct, recommend the readout that matches the biology you care about, and model the receptor where structural insight informs mutagenesis or ligand work.
Key Advantages
Expression Level Treated As A Variable
Receptor density changes agonist potency and apparent efficacy. Construct design targets a level appropriate to the pharmacology being measured rather than the maximum achievable.
Readout Matched To Pathway
Second messenger, arrestin recruitment and label-free readouts report different events. We recommend based on the receptor coupling and the question, and note what each readout will miss.
Structural Modelling Where It Helps
Receptor models, including active and inactive states where templates allow, support mutagenesis design, ligand docking and interpretation of unexpected pharmacology.
Host Background Considered
Endogenous receptor and signalling component expression in the chosen host is checked, since background activity is a frequent source of confusing results.
Where This Service Is Used
How the Work Is Performed
What We Need From You
What You Receive
Questions We Are Asked Before Scoping
Why does our receptor not reach the surface?
- Common causes are missing signal peptide requirements, misfolding, absent chaperones or an unsuitable host. Sequence and structural analysis usually narrows it, and construct variants are designed to test the likely causes in parallel.
Which assay readout should we use?
- It depends on coupling and on whether pathway-biased behaviour matters. We recommend one primary and one orthogonal readout, because single-readout pharmacology is frequently misleading.
Can you model a receptor with no structure?
- Yes, using family templates and prediction, with confidence reported per region. Binding site conclusions from such models are treated as hypotheses for mutagenesis rather than as established.
Interpretation and Limitations
This is a computational (in silico) service. Designs and predictions prioritise hypotheses and direct experimental effort; they do not by themselves establish that an edit, construct, molecule or assay will perform as intended. Laboratory execution — editing, cloning, expression, synthesis and testing — is planned with you and carried out by your own team or a qualified partner. Deliverables are for research use only and are not intended for diagnostic or therapeutic use.
Specifications
| Item | Specification | Notes |
|---|---|---|
| Typical turnaround | 2–4 weeks | Including structural modelling |
| Modelling | Active and inactive states | Where suitable templates exist |
| Readouts assessed | cAMP, Ca²⁺, arrestin, label-free | Recommendation per receptor |
| Output | Construct, assay plan, models | With ready-to-open molecular viewer sessions |
Service Workflow
Scientific Consultation
We discuss the objective, the decision it supports and the material and data you already hold.
Feasibility Review
We check that the target, system and available information can support the approach, and say plainly where they cannot.
Technical Proposal
Scope, methods, deliverables, timeline and price are confirmed in writing, together with the limitations we expect to report.
Design and Analysis
The design work runs on documented tools and parameters, with quality checks and alternatives compared where that is informative.
Delivery and Follow-Up
You receive the designs, the supporting analysis and a validation plan, plus support interpreting the results once the experiments run.
Is This the Right Service for You?
Choose this service when
Consider another service when
What Goes Wrong, and How We Handle It
The failure modes that produce confident-looking results which do not survive the next experiment. Each one is designed against rather than discovered afterwards.
Case Studies
Illustrative of the shape this work takes. Details are generalised, no client or target is identified, and scope and outcome vary with the system in question.
Note: ICDMO delivers computational (in silico) services. Results prioritise hypotheses for testing; they do not by themselves establish binding, biological activity, efficacy or safety. All deliverables are for research use only and are not intended for diagnostic or therapeutic use. Downstream experimental work is scoped separately and executed through qualified partners.
Get in Touch
about GPCR Cell Line & Assay Design
Tell us about the target, the data you hold and the decision the result needs to support. A scientist reviews every enquiry and replies within one business day.